Generation Bio (GBIO)
(Delayed Data from NSDQ)
$2.40 USD
+0.21 (9.59%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $2.45 +0.05 (2.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.40 USD
+0.21 (9.59%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $2.45 +0.05 (2.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
Zacks News
Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Generation Bio (GBIO) delivered earnings and revenue surprises of 17.86% and 249.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 6.05% and 3.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Generation Bio (GBIO) delivered earnings and revenue surprises of -14.81% and 26.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 0% and 89.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Generation Bio (GBIO) delivered earnings and revenue surprises of -211.11% and 34.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -29.27% and 5.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of 4.08% and 88.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -35.90% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
by Zacks Equity Research
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
Can Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 183.8% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 176% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 174% Upside in Generation Bio Co. (GBIO): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 173.7% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Upgraded to Buy: Here's Why
by Zacks Equity Research
Generation Bio Co. (GBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Generation Bio Co. (GBIO)? Wall Street Analysts Think 505%
by Zacks Equity Research
The consensus price target hints at a 504.9% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Earnings Season Could Be Great for Generation Bio (GBIO)
by Zacks Equity Research
Generation Bio (GBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Generation Bio (GBIO) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
Generation Bio (GBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.